NSCLC Patients in Remission Have New Options for Maintenance Therapy

Dr. Kirshner is Partner and Director of Research, Hematology Oncology Associates of Central New York, East Syracuse; and Chief of Oncology, Community General Hospital, Syracuse. View profile. 1. In your view, which development in lung cancer that has occurred in 2009 could have the most significant impact on oncology?In my opinion, the top story in lung cancer for 2009 comes from new data about the role of maintenance therapy for patients whose non−small cell lung cancer is in remission. Two reports...

NOT A MEMBER?

OncologySTAT registration is FREE and takes less than a minute to complete. Registration provides instant access to 100+ Elsevier cancer-related journals, journal scans, daily medical and regulatory news, professional drug and interactions databases, chemotherapy regimens, and InfoBLAST - OncologySTAT's weekly e-newsletter.

 

Editors' Choice

Pertuzumab Monotherapy in HER2-Negative Metastatic Breast Cancer

Advisory and Editorial Boards

Meet OncologySTAT's Advisory and Editorial Boards that represent community practitioners and academic specialists with cross-disciplinary expertise.

Cancer Types Spotlight

  • Bladder
  • Bone
  • Breast
  • Breast (ER Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Bladder
  • Bone
  • Breast
  • Breast (ER Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin (Melanoma)
  • Skin (Non-Melanoma)
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration